ITGAM and neoplasm: Flow cytometry analysis demonstrated that compared to the control group, the proportion of MDSCs (CD11b+ and Gr‐1+) increased from 46.4% to 58.6% in the tumor tissues of the LPS‐treated group (Figure 1G,H).